VERV

Verve Therapeutics
VERV

Overview Fund Activity
Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

134 hedge funds and large institutions have $847M invested in Verve Therapeutics in 2023 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 24 reducing their positions, and 14 closing their positions.

Holders
134
Holders Change
+13
Holders Change %
+10.74%
% of All Funds
2.14%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
27
Increased
58
Reduced
24
Closed
14
Calls
$7M
Puts
$4.99M
Net Calls
+$2M
Net Calls Change
+$1.64M

Top Buyers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$64.1M
2
JPMorgan Chase & Co
2
JPMorgan Chase & Co
New York
$33.2M
3
CC
3
Casdin Capital
New York
$39.2M
4
Fidelity Investments
4
Fidelity Investments
Massachusetts
$87.2M
5
LGM
5
Logos Global Management
California
$2.85M

Top Sellers

1
NHAS
1
Novo Holdings A/S
Denmark
$0
2
APM
2
Avidity Partners Management
Texas
$3.78M
3
Citadel Advisors
3
Citadel Advisors
Florida
$3.15M
4
PHS
4
PFM Health Sciences
California
$0
5
RG
5
Redmile Group
California
$10.7M
Name Market Value Shares Shares
Change 		Shares
Change %
HT
151
HAP Trading
New York
– – – –
CAL
152
Capital Advisors Ltd
Ohio
$0 31 +31 New
3 4 5 6
7